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Abstract 
Background: Despite recent advances in colorectal cancer (CRC) diagnosis and population screening programs, the 
identification of patients with preneoplastic lesions or with early CRC stages remains challenging and is important for 
reducing CRC incidence and increasing patient’s survival.
Methods: We analysed 76 colorectal tissue samples originated from early CRC stages, normal or inflamed mucosa by 
label‑free proteomics. The characterisation of three selected biomarker candidates was performed by immunohisto‑
chemistry on an independent set of precancerous and cancerous lesions harbouring increasing CRC stages.
Results: Out of 5258 proteins identified, we obtained 561 proteins with a significant differential distribution among 
groups of patients and controls. KNG1, OLFM4 and Sec24C distributions were validated in tissues and showed differ‑
ent expression levels especially in the two early CRC stages compared to normal and preneoplastic tissues.
Conclusion: We highlighted three proteins that require further investigations to better characterise their role in early 
CRC carcinogenesis and their potential as early CRC markers.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Colorectal cancer (CRC) is the third leading cause of 
death by cancer in the western world. Population screen-
ing programs for identification of patients with pre-
neoplastic lesions or early CRC stages is important for 
reducing CRC incidence and for increasing patient’s 
survival. CRC shows a multi-stage progression with 
sequential accumulation of genetic alterations that might 
occur over a long period of time and with absence of 
symptoms [1]. Colonoscopy is the method of choice for 
the diagnosis of CRC [2]. It can also be used for broad 
population screening but is hampered in this setting by 
its cost, discomfort and risks for the patients. Different 
non-invasive tests as faecal occult blood test (FOBT) 
and faecal immunochemical test (FIT) are used for CRC 
screening [3], but their use is not generalised in all coun-
tries. Indeed, despite that some of these are cost-effective, 
they often lack of sensitivity as well as specificity. Hence 
early non invasive specific and sensitive markers are still 
awaited for screening purposes.
Recent advances in genomics, proteomics and metab-
olomics have increased the list of potential biomarkers 
associated with CRC and contributed to our understand-
ing of its development [4]. Due to the heterogeneous 
nature of CRC, a biomarker signature (panel of several 
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proteins) may be more effective for screening test devel-
opment than a single biomarker.
Dysplastic and neoplastic tissues regulate protein 
expression and produce protein profiles that might be 
correlated to precancerous or cancerous specific progres-
sion. To capture these events, it is adequate to investigate 
protein changes directly in the colon mucosa. Formalin-
fixed paraffin-embedded (FFPE) tissues stored in hospital 
biobanks represent a valuable resource for retrospective 
analysis as larger populations can be studied, enhancing 
the probability to identify significant and specific poten-
tial CRC biomarkers.
Hence our aim was to screen FFPE specimens includ-
ing early CRC stages using label free proteomics. We vali-
dated three selected proteins by immunohistochemistry 
(IHC) on a larger independent sample set containing nor-
mal tissue, CRC and precancerous lesions for their full 
histological characterisation and for partial validation of 
the proteomic results obtained.
Methods
Patients and FFPE tissue samples
Human FFPE tissue blocks were obtained from the 
Biobank of the Liège University Hospital, Belgium. This 
study received approval by the Ethics reviewing board 
of the University Hospital of Liège, Belgium (15 Octo-
ber 2014) (internal ref number: 2005-144). The clinical 
and pathological characteristics of the patients are sum-
marized in Table 1 for the patients included in the pro-
teomic analysis (left panel) and for the patients used for 
the IHC validation (right panel). We selected for the dif-
ferential proteomic analyses some tissue samples from 
early CRC stages (namely pT1N0M0 and pT2N0M0) and 
compared these to normal and inflamed tissues taken 
from diverticular diseases. We characterised IHC tissue 
distributions of some selected proteins in all possible 
precancerous and cancerous stages, from adenomas with 
low grade dysplasia to pT4NM of CRC. Different exclu-
sion criteria were applied: no other digestive disease or 
cancer 6 months before or after resection, no hereditary 
nonpolyposis CRC and no familial adenomatous poly-
posis. The control group was composed of patients with 
diverticular diseases and the selected tissues treated were 
isolated within the diverticulitis zone itself [named diver-
ticulitis inflammatory (DI)] or in the adjacent normal tis-
sue [named diverticulitis healthy (DH)]. All pathological 
stages (normal, inflammatory, adenomas and cancers) 
were assessed according to clinical diagnosis standard-
ised guidelines and according to the AJCC TNM staging 
system [5–8].
None of the CRC cases had been treated by chemother-
apy or radiotherapy before surgical resection.
All the tissue specimens were processed using a stand-
ard procedure for formalin fixation (24  h) and were 
embedded in paraffin as done for routine clinical analy-
sis [9]. Histological diagnosis of normal tissues, inflam-
mation, adenocarcinoma and adenoma types and grades 
were confirmed by trained anatomopathologists (N.B., 
J.S.) after microscopic examination of the hematoxylin 
and eosin (H&E) stained sections.
Pre‑treatment of FFPE slices before the proteomic analysis
In order to obtain an enriched population of epithelial 
cells (either normal or neoplastic), the tissue sections 
(thickness 6 µm) were macrodissected. The percentage 
of tumoral cells was established by trained anatomo-
pathologists (N.B., J.S.) and is communicated in Table 1. 
The H&E sections were scanned using Hamamatsu 
Photonics K.K. (magnification 40×) and uploaded into 
the CYTOMINE application [10] to measure the sur-
face of the macrodissected Zones. A constant surface 
of tissue was processed per patient and correspond to 
300 mm2.
Proteomic discovery study
Figure 1 shows the workflow of the proteomic discovery 
experiment.
FFPE sample preparation
Slicing, deparaffinization and  rehydration FFPE sec-
tions for a total of 300 mm2 of macrodissected tissue per 
patient were treated as previously described [11]. Depar-
affinization was performed by incubating the samples 
twice in xylene and followed by ethanol (100%) incubation 
(5  min each). Centrifugation was applied at 15,000  rpm 
for 5 min at room temperature between every 1 mL sol-
vent changes. The material placed in the microtube was 
further evaporated to dryness with a speed-vacuum at 
room temperature for 5 min. The material was weighed 
before and after deparaffinization.
FFPE‑FASP™ application The tissue sections after 
deparaffinization were weighed dry and resuspended in 
the universal protein extraction buffer (UPX) provided in 
the FFPE-FASP™ Protein Digestion Kit. All downstream 
steps of digestion and peptide extraction were performed 
using 2.5 mg of dry material resuspended in 50 mL of UPX 
buffer, according to the manufacturer instructions (Expe-
deon, Cambridge, UK). The protein concentration of each 
sample was determined using the RCDC Protein Assay Kit 
(BioRad, Hercules, CA, USA) before FFPE-FASP™ treat-
ment. For each disease category, four pools were com-
posed of four–five patients using equal quantity of mate-
rial of each individual sample protein digest (Fig. 1).
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Sample conditioning and  spiking with  internal stand‑
ards The quantity of material present in each sample 
was determined using the bicinchoninic acid (BCA) pro-
tein assay (Pierce, Rockford, IL, USA). For each sample, 
5  μg of peptides per condition (or pool) was desalted 
using C18 resin pipet tips (Zip Tip, Millipore Corp, 
Billerica, MA, USA) according to the manufacturer’s 
instructions. The eluted fractions were pooled and dried 
using a speed-vacuum at room temperature. The dry pel-
lets were stored at −20 °C until further analysis. Prior to 
injection onto the 2DnanoUPLC system and MSE analy-
sis, 2.5 µg of the digested proteins were resuspended in 
9 μL of 100 mM ammonium formate solution adjusted 
to pH 10. The samples were spiked with the MassPREP™ 
Digestion Standard Mixture (MPDS mix) (Waters Corp., 
Milford, USA) which contains a mixture of yeast enolase 
(ENO1, P00924), rabbit glycogen phosphorylase b (GPB, 
P00489), yeast alcohol dehydrogenase (ADH, P00330) 
and bovine serum albumin (BSA, P02769) digest. The 
corresponding ADH quantity spiked per sample injec-
tion was 150 fmol.
LC–MS/MS analysis
All samples were injected on a 2D-nanoAquity UPLC 
(Waters, Corp., Milford, USA) coupled online with a Q-
Tof Synapt HDMS™ G2 system (Waters, Corp, Milford, 
USA) using ion mobility as an additional separation. 
The chromatographic peptide separation was performed 
on the nanoUPLC system using a similar 2D-run in a 
reversed phase pH 10/reversed phase pH 3 dilution con-
figuration. Briefly, the samples were loaded at 2  μL/min 
(20 mM ammonium formate solution, pH 10) on the first 
column (X-Bridge BEH C18, 5  µm) and subsequently 
eluted in five steps (10, 14, 16, 20 and 65% acetonitrile). 
These five fractions were desalted on the trap column 
(Symmetry C18, 5, 180 µm, 20 mm) after a 10 times online 
dilution to pH 3 and subsequently separated on the BEH 
C18 1.7 µm analytical column (75 µm, 250 mm, Waters, 
Corp., Milford, USA). The trap column conditions were 
a 250 nL/min flow rate 250 nL/min a gradient from 97% 
solvent A to 65% solvent A in 90 min with solvent A: 0.1% 
(v/v) formic acid in water and solvent B: 0.1% (v/v) formic 
acid in acetonitrile. The mass spectrometer was operated 
Fig. 1 Proteomic discovery experiment workflow. Tissue section manual macrodissections (see line surrounding specific tissue area selected) were 
performed to obtain an enriched population of epithelial cells. The FASP‑FFPE™ protein digestion kit was applied on each patient tissue (using 
around 300 mm2 of 6 µm tissue section). FASP‑FFPE™ was applied on the dry material resuspended in the UPX buffer. Four to five patient sample 
digests were grouped per pool analysed. Four pools per disease groups were analysed by label‑free proteomics differential analysis. UPX universal 
protein extraction
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in positive ion mode. The data acquisition was performed 
in the 50–1500 m/z range with a scan time of 0.6  s and 
collision energy voltages set in independent alternative 
scanning (MSE) mode. The IMS parameters used were an 
IMS cell pressure of 2.5 mbar, a variable IMS wave velocity 
ranging from 850 to 1200 m/s and a wave height of 40 V. 
The singly charged peak of polysiloxan at m/z 445.12003 
was used as lock mass and spectra were calibrated manu-
ally post acquisition.
Data analysis
Raw data analysis, protein identifications and differential 
analysis Raw data were processed (deconvoluted, deiso-
toped), proteins identified/quantified and the differential 
analysis using relative quantification were all performed 
with Nonlinear Dynamics’ Progenesis program, version 
1.1.4.8.32.42.175 (Waters, Newcastle on Tyne, UK). The 
parameters used for data processing were as follows: MS–
TOF resolution and chromatographic peak width were set 
to automatic, low-/elevated-energy detection thresholds 
was 250/100 counts respectively and identification inten-
sity threshold was set to 1500. For protein identifications, 
the UniProt human database without isoform was used as 
the reference (canonical sequence data with 20,280 entries, 
UniProt release 2011_12—December 14, 2011). The search 
parameters used were as follows: carbamidomethylation (C) 
as fixed modification, oxidation (M) and phosphorylation 
(STY) of peptides as variable ones, maximum two possible 
trypsin miss-cleavages was allowed, minimum fragment 
ion matches per peptide was set at 3, the minimum frag-
ment ion matches per protein was set at 7 with minimum 
two peptides matches per protein (irrespective of possible 
peptide sequence redundancy). The maximum false positive 
discovery rate (FDR) on protein identification was set to 4%.
Differential analysis on nonlinear dynamics’ progen-
esis was done not considering protein isoforms and these 
were “grouped” in only one protein identification hit. 
Only the proteins identified in minimum 80% of sam-
ples whatever disease group was considered for further 
analysis. A normalisation was applied using the peptides 
identified as unique to one protein (=non-conflicting 
features). The Anova test was applied to compare the 
four categories of samples (DH vs. DI vs. pT1N0M0 vs. 
pT2N0M0) as well as the two cancer stages (pT1N0M0 
vs. pT2N0M0). The proteins identified with at least two 
peptides, showing significant p value (≤0.05) and an 
absolute fold change (Fc) ≥2 were selected and consid-
ered as potential biomarkers.
Selection of the three proteins of interest
The selection of the three proteins of interest was done 
according to the experimental results obtained (high Fc and 
significance in the two comparisons addressed: pT1N0M0 
vs. pT2N0M0 and DH vs. DI vs. pT1N0M0 vs. pT2N0M0) 
and according to data available in the literature.
IHC validation of three proteins of interest
Immunohistochemistry of kininogen‑1, transport protein 
Sec24C and olfactomedin‑4
The 6  µm section slices mounted on glass slide were 
heated at 60 °C, deparaffinized in xylene and rehydrated 
in graded isopropanol baths. Antigen retrieval was per-
formed with a steamer for 10  min in target retrieval 
solution (DAKO) for all three antibodies. Endogenous 
peroxidase activity was quenched by incubation with 3% 
hydrogen peroxide for 10  min, followed by incubation 
with Protein block serum-free ready-to-use (DAKO) for 
30 min to block nonspecific binding. The sections were 
subsequently incubated with the primary antibodies 
in appropriate dilutions overnight at 4  °C for the anti-
olfactomedin-4 antibody, cat ab85046 (ABCAM) and 
anti-Sec24C antibody, cat ab122635 (ABCAM). The 
incubation for kininogen-1 (KNG1) IHC was performed 
1 h at room temperature using anti-kininogen antibody, 
cat sc-25799 (Santa-Cruz Biotechnology). The sec-
tions were incubated for 30  min with EnVision +  Sys-
tem-HRP labelled polymer anti-rabbit (DAKO). The 
chromogen used was 3,3′-diaminobenzidine and coun-
terstaining was done with hematoxylin. The isotype 
controls used for all three antibodies were performed 
with the same method as used for each specific IHC, see 
in Figs. 2, 3 and 4 the illustrating picture (named nega-
tive control).
Quantitative analysis of IHC staining and statistics IHC 
results were evaluated in at least three areas by two inde-
pendent scorers (by FQC, CM) not trained in anatomopa-
thology and without prior knowledge of clinical data and 
proteomic results. Immuno-stained sections were scored 
positive if epithelial cells showed specific staining in the 
cytoplasm, in the plasma membrane and/or in the nucleus. 
A semi-quantitative score was determined by estimating 
the percentage of the stained cells and the averaged signal 
intensity. The scale used was ranging from none (score 0), 
weak (score 1), intermediate/weak (score 2), intermediate 
(score 3), intermediate/strong (score 4), strong (score 5) 
to very strong (score 6). Two particular patterns of stain-
ing were also identified: one was termed “gradation” and 
refers to an increasing gradient of intensity progressing 
from the base of the crypt to the upper epithelium bor-
der. The second pattern was named “heterogeneity” and 
was used to describe areas where some cells were posi-
tive and some were negative. The semi-quantitative scores 
attributed to these particular patterns were based on the 
average value of the scores corresponding to the different 
fields analysed.
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Statistical analyses were achieved using GraphPad 
Instat vs 3 and Prism softwares vs 6. The Kruskal–Wallis 
test was used to compare each groups scores as defined 
above ranging from 0 to 6. Results were considered sig-
nificant if the associated p value was <0.05.
Gene expression meta‑analysis using published microarray 
data
The meta-analysis of gene expression obtained from 
public microarray datasets was done using the gene 
expression commons (GEXC) platform [12]. The inde-
pendent datasets of adequate clinical scopes included 
were GSE13471 [13], GSE13428 [14] and GSE62932, 
including the tissues analysis of 96 patients. This plat-
form aims at normalising microarray data against the 
common reference to obtain an absolute gene expres-
sion level within a specific tissue or organism. All gene 
expression datasets included were acquired using Affym-
etrixU133Plus2.0 human microarray and were obtained 
from NIH gene expression omnibus (accession no. GSE). 
We included only datasets originated from CRC or nor-
mal tissues (using Caucasian patients with known disease 
classification or classifications similar to our study). The 
CRC staging classification used for GSE62932 was dis-
tinct from the one used in our study using grades instead 
of pTNM stages. The data were normalised and the 
“standard robust average algorithm” generated the refer-
ence absolute “set expression level” [15]. The StepMiner 
algorithm allowed to assign to each protein a specific 
threshold which was used for result interpretation [16]. 
We built several populations and several models for the 
selected protein/gene candidates.
GO analysis
The GO analyses were performed using STRING db (v. 
10.0) and PANTHER db (V.11.0). Only the proteins found 
significant in “DH versus DI versus pT1N0M0 versus 
pT2N0M0” and “pT1N0M0 versus pT2N0M0” and show-
ing a minimum Fc of 2 were considered for GO analyses.
Results
Proteomic discovery on early CRC stages
Raw data and technical results
In order to detect proteins differentially distributed 
through early CRC stages and controls, we generated 
protein extracts from the 76 FFPE tissues regrouped 
Fig. 2 Immunohistochemical staining results obtained for OLFM4. a Representative staining pictures for OLFM4 in diverticular disease tissues (DI 
and DH), adenoma low grade (ADN LG)/high grade (ADN HG) and adenocarcinoma (ADK) tissues (scale bar 100 µm). b Quantification summary for 
OLMF4. The relative percentage calculated over all the categories of signal (from “none” to “gradation”) are detailed in the table. The highest value 
obtained is underlined in colour in each patient group represented by histograms and significant differences were obtained between DH versus pTis 
(p < 0.05), DH versus pT1 (p < 0.001), DH versus pT2 (p < 0.001), ADN low grade versus pT2 (p < 0.01), DI versus pT2 (p < 0.05) and pT2 versus pT3 
(p < 0.01). DH diverticulitis (adjacent normal tissue), DI diverticulitis inflammatory (diverticulitis zone itself ), ADK adenocarcinome, ADN LG adenoma 
low grade, ADN HG adenoma high grade
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into the four categories compared, as illustrated Fig.  1. 
Each pool was analysed as a biological replicate and the 
raw data file generated have been deposited to the Pro-
teomeXchange Consortium (http://proteomecentral.pro-
teomexchange.org) via the PRIDE partner repository [17] 
with the dataset identifier PXD005735 (Additional file 1: 
Table S1).
The percentage of variability obtained on the three 
proteins of the MPDS mix spiked and established using 
normalisation on ADH, was lower than 30% which is in 
agreement with the expected maximum variability of the 
technique [18].
Protein identifications/quantitations and differential analysis
We obtained 5258 proteins identified through 80% of 
the samples analysed and 3547 proteins quantified in 
the four groups (DH, DI, pT1N0M0 and pT2N0M0). 
We performed several comparisons: DH versus DI ver-
sus pT1N0M0 versus pT2N0M0 and pT1N0M0 versus 
pT2N0M0. A total of 561 proteins were found signifi-
cant in the four group comparison. We selected the 120 
proteins that were significant in both comparisons, see 
Additional file  2: Table S2. The proteins significant in 
pT1N0M0 versus pT2N0M0 are likely associated to CRC 
progression. Ten percent of these proteins have been pre-
viously associated with cancer development or CRC [19–
21] and are in bold in Additional file 2: Table S2. This also 
includes the results of two proteomic studies performed 
by two other groups [22, 23]. The proteins significantly 
differentially distributed between normal enterocytes 
and cancer cells isolated by laser microdissection are in 
blue [22] and the proteins significantly different between 
stromal cells of colon adenocarcinoma and non-neoplas-
tic colon mucosa are in green [23] in Additional file  2: 
Table S2.
Selection of some potential protein biomarkers and their 
validation
To partially validate our proteomic results, we selected 
three proteins (in red in Additional file  2: Table S2) that 
were found differentially distributed in one or both com-
parisons: (pT1N0M0 vs. pT2N0M0) and (DH vs. DI vs. 
pT1N0M0 vs. pT2N0M0). The olfactomedin-4 (OLFM4) 
showed a maximum Fc of 28.18 (p value = 0.039), protein 
transport protein Sec24C (Sec24C) showed a maximum Fc 
of 33.14 (p value =  0.028) in the four group comparison. 
The KNG1 present a maximum Fc of 3.92 (p value = 0.037) 
in the pT1N0M0 versus pT2N0M0 analysis. The selection 
Fig. 3 Immunohistochemical staining results obtained for Sec24C. a Representative staining pictures for Sec24C in diverticular disease tissues (DI 
and DH), adenoma low grade (ADN LG)/high grade (ADN HG) and adenocarcinoma (ADK) tissues (scale bar 100 µm). b Quantification summary for 
Sec24C. The relative percentage calculated over all the categories of signal (from “none” to “gradation”) are detailed in the table. The highest value 
obtained is underlined in colour in each patient group represented by histograms and significant differences were obtained between DH versus 
pT1N0M0, DH versus pT2N0M0, ADN low grade versus pT1 (p < 0.05), ADN low grade versus pT2 (p < 0.001), pT1 versus pT3 (p < 0.01), pT1 versus 
pT4 (p < 0.05), pT2 versus pT3 (p < 0.001), pT2 versus pT3 (p < 0.001), DI versus pT2 (p < 0.05) DH diverticulitis (adjacent normal tissue), DI diverticuli‑
tis inflammatory (diverticulitis zone itself ), ADK adenocarcinome, ADN LG adenoma low grade, ADN HG adenoma high grade
Page 8 of 13Quesada‑Calvo et al. Clin Proteom  (2017) 14:9 
of these three proteins for IHC validation was done accord-
ing to the value of the Fc and p value obtained, on the 
availability of commercial IHC antibodies as well as data 
available in the literature. Indeed, some of these were not 
yet or seldom reported in CRC despite often associated to 
tumorigenesis or cancer progression in general and were 
more abundant in tumor than in normal tissues.
Tissue distribution of OLFM4
Representative pictures of OLFM4 staining are shown in 
Fig. 2a for each pathology group. The results of the semi-
quantitative analysis of OLFM4 staining are summarised 
in Fig.  2b. The chart computes the relative percentages 
obtained in the different categories defined for the differ-
ent disease groups. The statistical analysis done using the 
semi-quantitative scores (ranging from 0 to 6) showed 
significant differences.
OLFM4 staining was present in the basal crypt cells 
and in luminal surface epithelium. It was detected in the 
stromal cells such as inflammatory cells and fibroblasts, 
with percentages and intensities both increasing from 
precancerous to cancerous tissues. This increase was only 
observed up to CRC stage 2 and was less intense in CRC 
stages 3 and 4. Some epithelial cells in colonic mucosa 
distant from the original tumor showed strong positive 
signal. OLFM4 staining in epithelial or stromal cells was 
not significantly correlated with age, gender, N or M clas-
sification or tumor localisation.
Tissue distribution of Sec24C
Representative pictures of Sec24C staining are shown in 
Fig. 3a for each pathology group. The results of Sec24C 
semi-quantitative analysis are summarised in Fig.  3b. 
The chart computes the relative percentages obtained in 
the different categories defined for the different groups. 
Sec24C was found significantly more abundant in epi-
thelial cells of pT1 and pT2N0M0 compared to DH (p 
value <0.01 and p value <0.001, respectively). Sec24C 
was also more abundant in the cells of the crypts and at 
the surface epithelium than in the chorion. The statisti-
cal analysis done using semi-quantitative scores provided 
significant differences.
A more pronounced signal (percentage of cells or 
labelling intensity within positive cells) for Sec24C was 
observed in the stroma of diverticular disease tissues (in 
both DH and DI) and in early CRC stages (pT1–pT2). 
Fig. 4 Immunohistochemical staining results obtained for KNG1. a Representative staining pictures for KNG1 in diverticular disease tissues (DI 
and DH), adenoma low grade (ADN LG)/high grade (ADN HG) and adenocarcinoma (ADK) tissues (scale bar 100 µm). b Quantification summary 
for KNG1. The relative percentage calculated over all the categories of signal (from “none” to “gradation”) are detailed in the table. The highest value 
obtained is underlined in colour in each patient group represented by histograms and significant differences were obtained between DH versus pT2 
(p < 0.001), DH versus pT3 (p < 0.05), DH versus pT4 (p < 0.01), ADN low grade versus pT2 (p < 0.001), ADN low grade versus pT3 (p < 0.05), ADN 
low grade versus pT4 (p < 0.01), ADN high grade versus pT2 (p < 0.05), pT1 versus pT2 (p < 0.05) DI versus ADN low grade (p < 0.05). DH diverticu‑
litis (adjacent normal tissue), DI diverticulitis inflammatory (diverticulitis zone itself ), ADK adenocarcinome, ADN LG adenoma low grade, ADN HG 
adenoma high grade
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The inflammatory cells within the stroma that were posi-
tive were predominantly macrophages with a positive 
staining of the cytoplasmic vesicles. Moreover the neo-
plastic cells progressing as a migrating front also showed 
an important positive Sec24C expression.
Tissue distribution of KNG1
Representative pictures of KNG1 staining are shown in 
Fig. 4 for each pathology group. The results of the KNG1 
semi-quantitative analysis are summarised in the Fig. 4b. 
The chart computes the relative percentages obtained in 
the different categories defined for the different groups. 
The KNG1 expression was significantly increased in can-
cerous lesions compared to normal and dysplastic tissues.
GEXC meta‑analysis
The results obtained for the transcriptional expression level 
of the proteins discriminant in the comparison pT1N0M0 
versus pT2N0M0 are summarised in Additional file 2: Table 
S2. The GEXC analysis generated transcriptional expres-
sion results for OLFM4, Sec24C and KNG1 that are illus-
trated Fig. 5a–c respectively. The expression of genes do not 
always correlate perfectly with the protein levels observed, 
which can be also explained by the difference of CRC 
stages—grades studied in the series of patients included in 
these analyses. However Sec24C and KNG1 gene expres-
sion levels increased along with the corresponding pro-
tein levels in healthy tissues and in CRC stages 1 and 2. 
The Sec24C decrease obtained in later CRC stages was in 
accordance with what was observed in our IHC results. 
Hence similar distribution tendencies in the two independ-
ent cohorts of tissue samples could be obtained. However, 
an inverse tendency was obtained for OLFM4 gene expres-
sion and protein abundance. The expression levels of the 





The understanding of the mechanisms and the identifi-
cation of markers of CRC development and progression 
are both very important; especially at early stages when 
patients are still asymptomatic. Hence we focused on the 
comparison of tissue proteomes of two early CRC stages 
(pT1N0M0 and pT2N0M0) with those of normal and 
Fig. 5 GEXC meta‑analysis of OLFM4, Sec24C and KNG1. a Graphical representation of the Probeset meta profile obtained for each transcript. The Y 
axis represents the expression level (normalised in log2 scale) with an histogram graph illustrating the distribution of the gene expression within the 
colour gradient spread over the whole distribution of the transcript calculated with the patient data set included. The colour bar gradient displays 
the gene expression activity and the distribution of percentiles (down regulated in blue, upregulated in red). b Absolute gene expression of OLFM4, 
Sec24C and KNG1: each model is figured by boxes and connecting lines representing the biological context and relationships among populations of 
patients. A population contains several microarray data. “Tumor” contains colorectal adenocarcinoma data (stage non specified), “normal” contains 
the matched normal colon data, “HC” refers to healthy control data (obtained using colon tissue), stage 1–4 refer to the CRC dataset with the cor‑
responding stages. c Number of replicates included into the considered populations and the distributions of the specific protein expression levels 
within the evaluated models. HC healthy control, GEO gene expression omnibus
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inflamed control tissues (DI and DH). Inflamed tissues 
inclusion in the experimental design allowed us to iden-
tify potential inflammation-related proteins among the 
potential early CRC markers highlighted. Our proteomic 
study showed altered protein expression in early CRC tis-
sues, a focus rarely addressed by proteomics. We showed 
by both proteomics and IHC the altered tissue expression 
of OLFM4 and KNG1, especially in early CRC stages. 
The abnormal production of Sec24C in these early CRC 
stages was also reported for the first time.
We previously demonstrated the ability to obtain an 
efficient and repeatable protein extraction using limited 
quantities of FFPE material before data-independent 
label-free analysis [24]. We performed macrodissection 
to favor the selection of cells of interest, removing abun-
dant stromal tissue surrounding the tumor and decreasing 
the impact of response factors originated from neighbor-
ing tissues. Moreover the proteomic technology used was 
robust and suited to address such clinical question thanks 
to the high resolution, high speed of the mass spectrom-
eters used in combination with the advanced computa-
tional methods allowing confident protein identifications 
and differential analysis [25–28]. We used two dimen-
sional nanoUPLC enabling efficient chromatographic 
peptides separation while keeping data acquisition length 
reasonable. We could reach repeatable signal as techni-
cally expected using data independent analysis with MSE 
on Synapt G2, combining high resolution with ion mobil-
ity separation as supplementary dimension [18].
The 561 potentials biomarkers highlighted (Fc ≥2) 
in the four group comparison corresponds to 10.67% 
(15.81%) of the proteome identified (quantified). This 
percentage of potential candidates selected by label-free 
proteomics albeit applied on FFPE samples is in agree-
ment with proteomic results of other teams using other 
MS instruments, statistics and other sample types and 
biological matrix [29, 30].
Based on proteomic results and data available in the 
literature, we selected three proteins found differentially 
abundant in early CRC tissues for IHC confirmation. We 
could characretise their IHC profiles in a second and larger 
independent set of samples/patients, including normal tis-
sues, adenoma, pTis and the four progressive CRC stages 
(from pT1NM to pT4NM). Moreover, their respective 
transcriptional expression levels evaluated using GEXC on 
a third independent set of samples/patients also corrobo-
rated some of our proteomic and IHC findings.
OLFM4 is generally expressed in the basal crypt cells 
and is considered as a specific stem cell protein [31–35]. 
It is involved in cancer development via antiapoptotic 
action, in cell proliferation, cell adhesion and metastasis 
[36–38]. In our study, IHC OLFM4 level appeared signifi-
cantly higher in the epithelial cells of pTis, pT1 and pT2 
while it was significantly lower in pT3 (and even lower 
in pT4) as previously shown [39]. Interestingly, OLFM4 
was also detected in stromal cells such as inflammatory 
cells and fibroblasts and this with a higher intensity in 
adenoma and adenocarcinoma tissues. But again with 
lower signals for pT3 and pT4 compared to other tissues. 
In the study of Seko et al. [38], 36% of CRC cases tested 
showed an OLFM4 tumor cytoplasmic staining. Moreo-
ver they observed extracellular staining far from the orig-
inal tumor, however this could not be confirmed in this 
study. OLFM4 is secreted and may be detected in serum 
and plasma therefore representing a good candidate CRC 
marker as previously suggested for gastric cancer [35, 36].
Sec24C is an essential coat protein II (COPII) component 
and COPII is involved in protein transports from the endo-
plasmic reticulum (ER). Recently the AKT kinase was pro-
posed as a new player in the control of ER protein transport 
[37]. Indeed AKT phosphorylates the two Sec24 isoforms 
(Sec24D and Sec24C) consequently affecting transport. 
AKT leads to cell survival, stimulates cell growth and 
increases proliferation. In CRC and other cancers, genetic 
aberrations lead to AKT hyperactivation, while adenoma 
tissues were found to overexpress AKT [40]. Finally inhi-
bition of AKT decreases SEC24 protein levels [37]. The 
distribution of Sec24C that we observed showed a general 
increase in adenoma and early CRC stages, while its expres-
sion appeared decreased in more advanced CRC stages. 
This is in line with AKT overexpression known as an early 
event in colon carcinogenesis [40]. Altogether, these obser-
vations may provide further explanations of our results.
KNG1 is a cysteine proteinase inhibitor that can be 
cleaved into six subchains. It is implicated in blood coag-
ulation and inflammatory response and was recently 
described as a serum biomarker for the early detection 
of advanced colorectal adenoma and CRC [41]. Indeed, 
KNG1 serum levels were lower in postoperative than in 
preoperative CRC patients. Their hypothesis to explain 
this observation was that an increased production of 
KNG1 derives from tumor tissues. Accumulating stud-
ies continue to demonstrate higher levels in different 
biological fluids (urine and sera) from different cancers 
[42, 43]. In this respect, our study confirmed that KNG1 
was detected in FFPE tissue by proteomics and IHC with 
higher signal intensity and in more cells in the differ-
ent CRC stages. Mostly in early CRC compared to ade-
noma and control tissues. Although its mechanistic role 
remains unclear in cancer, KNG1 could have antiangio-
genic properties and inhibitory actions on proliferation 
of endothelial cells [44]. Previous studies have shown 
lower levels of KNG1 in urine or sera of ovarian carci-
noma cases and cervical cancer patients respectively [45, 
46]. But in these studies the protein detected was KNG1 
light chain and not the entire protein. Hence detection 
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of KNG1 as a whole or specifically its light chain could 
be futher investigated as promising targets for cancer 
diagnosis.
Interestingly OLFM4 and Sec24C showed a more abun-
dant expression in early than in later CRC stages which is 
of particular value when aiming at early diagnosis. How-
ever their distributions at the systemic level should first 
be investigated to establish their value as potential early 
and non invasive CRC biomarkers.
This partial validation of our proteomic results as well 
as converging observations with other works in a related 
context [19–23] suggest that other proteins highlighted 
in this work might also be potential biomarkers associ-
ated to early CRC stages.
Conclusion
Our data confirm the ability of a research strategy based 
on proteomic screening using FFPE tissue samples, fol-
lowed by IHC confirmation on an independent set of 
samples/patients to identify potential protein markers 
associated to early CRC stages. We were able to confirm 
abnormal expression of OLFM4 and KNG1 in CRC tis-
sues, especially in early pTNM CRC stages. This could 
also be observed but more moderately in precancerous 
lesions. We showed for the first time an overexpression 
of Sec24C in early stages and a decrease in later stages 
of CRC. Further studies on these proteins are warranted 
to better understand their role in CRC progression and 
their potential as early diagnostic tools.
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